225 related articles for article (PubMed ID: 11501854)
1. Melphalan monitoring during hyperthermic perfusion of isolated limb for melanoma: pharmacokinetic study and 99mTc-albumin microcolloid technique.
Cattel L; Buffa E; De Simone M; Cesana P; Novello S; Dosio F; Ceruti M
Anticancer Res; 2001; 21(3C):2243-8. PubMed ID: 11501854
[TBL] [Abstract][Full Text] [Related]
2. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma.
Posner MC; Lienard D; Lejeune FJ; Rosenfelder D; Kirkwood J
Cancer J Sci Am; 1995; 1(4):274-80. PubMed ID: 9166488
[TBL] [Abstract][Full Text] [Related]
3. Blood leakage and melphalan leakage from the perfusion circuit during regional hyperthermic perfusion for malignant melanoma.
Hafström L; Hugander A; Jönsson PE; Westling H; Ehrsson H
Cancer Treat Rep; 1984 Jun; 68(6):867-72. PubMed ID: 6733699
[TBL] [Abstract][Full Text] [Related]
4. Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis.
Di Filippo F; Rossi CR; Santinami M; Cavaliere F; Garinei R; Anzà M; Perri P; Botti C; Di Angelo P; Pasqualoni R; Di Filippo S
In Vivo; 2006; 20(6A):739-42. PubMed ID: 17203758
[TBL] [Abstract][Full Text] [Related]
5. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.
Beasley GM; Caudle A; Petersen RP; McMahon NS; Padussis J; Mosca PJ; Zager JS; Hochwald SN; Grobmyer SR; Delman KA; Andtbacka RH; Noyes RD; Kane JM; Seigler H; Pruitt SK; Ross MI; Tyler DS
J Am Coll Surg; 2009 May; 208(5):706-15; discussion 715-7. PubMed ID: 19476821
[TBL] [Abstract][Full Text] [Related]
6. [Hyperthermic-antiblastic isolation perfusion for advanced melanoma of the limbs. The technic, immediate results and a review of the literature].
Decian F; Balletto N; Camerini G; Depaoli M; D'Aniello R; Ameri A; Brisighella A; Bonalumi U; Bachi V; Civalleri D
Minerva Chir; 1990 Oct; 45(19):1227-37. PubMed ID: 2074944
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of isolated lung perfusion with melphalan for resectable pulmonary metastases, a phase I and extension trial.
Grootenboers MJ; Hendriks JM; van Boven WJ; Knibbe CA; van Putte B; Stockman B; De Bruijn E; Vermorken JB; Van Schil PE; Schramel FM
J Surg Oncol; 2007 Dec; 96(7):583-9. PubMed ID: 17999399
[TBL] [Abstract][Full Text] [Related]
8. Optimized procedure of real-time systemic leakage monitoring during isolated limb perfusion using a hand held gamma probe and 99mTc-HSA.
Casara D; Rubello D; Pilati P; Scalerta R; Foletto M; Rossi CR
Nucl Med Commun; 2004 Jan; 25(1):61-6. PubMed ID: 15061266
[TBL] [Abstract][Full Text] [Related]
9. Conventional isolated hyperthermic antiblastic perfusion in the treatment of recurrent limb melanoma.
Decian F; Mondini G; Demarchi R; Muzio G; Sementa A; Bocchio MM; Spirito C; Simoni G; Civalleri D
Anticancer Res; 1996; 16(4A):2017-24. PubMed ID: 8712736
[TBL] [Abstract][Full Text] [Related]
10. True versus mild hyperthermia during isolated hepatic perfusion: effects on melphalan pharmacokinetics and liver function.
Pilati P; Mocellin S; Rossi CR; Ori C; Innocente F; Scalerta R; Ceccherini M; Da Pian PP; Nitti D; Lise M
World J Surg; 2004 Aug; 28(8):775-81. PubMed ID: 15457357
[TBL] [Abstract][Full Text] [Related]
11. Isolated hypoxic hepatic perfusion with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques: a phase I and II study.
van Etten B; Brunstein F; van IJken MG; Marinelli AW; Verhoef C; van der Sijp JR; Guetens G; de Boeck G; de Bruijn EA; de Wilt JH; Eggermont AM
Ann Surg Oncol; 2004 Jun; 11(6):598-605. PubMed ID: 15172933
[TBL] [Abstract][Full Text] [Related]
12. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver.
Vahrmeijer AL; van Dierendonck JH; Keizer HJ; Beijnen JH; Tollenaar RA; Pijl ME; Marinelli A; Kuppen PJ; van Bockel JH; Mulder GJ; van de Velde CJ
Br J Cancer; 2000 May; 82(9):1539-46. PubMed ID: 10789721
[TBL] [Abstract][Full Text] [Related]
13. [O2 utilization during hyperthermic extremity perfusion with rhTNF alpha and melphalan].
Haier J; Hohenberger P; Beck K; Schlag PM
Langenbecks Arch Chir; 1997; 382(3):128-33. PubMed ID: 9324610
[TBL] [Abstract][Full Text] [Related]
14. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
Kroon HM; Moncrieff M; Kam PC; Thompson JF
Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
[TBL] [Abstract][Full Text] [Related]
15. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
[TBL] [Abstract][Full Text] [Related]
16. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
[TBL] [Abstract][Full Text] [Related]
17. [Surgical treatment of malignant melanoma of the limbs combined with thermochemotherapy under extracorporeal circulation].
Truchetet F; Grosshans E; Kretz JG; Bartier JC; Laplanche G
Ann Dermatol Venereol; 1988; 115(5):573-85. PubMed ID: 3195954
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of melphalan leakage during hyperthermic isolation perfusion in melanoma of the limb.
Rauschecker HF; Foth H; Michaelis HC; Horst F; Gatzemeier W; Willenbrock C; Voth E; Kahl GF
Cancer Chemother Pharmacol; 1991; 27(5):379-84. PubMed ID: 1998997
[TBL] [Abstract][Full Text] [Related]
19. Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs.
Lejeune FJ; Eggermont AM
J Clin Oncol; 2007 Apr; 25(11):1449-50; author reply 1450-1. PubMed ID: 17416870
[No Abstract] [Full Text] [Related]
20. Hyperthermic antiblastic perfusion with TNFalpha and melphalan in stage III limb melanoma patients: A phase I - II SITILO study.
Di Filippo F; Rossi CR; Garinei R; Anzà M; Cavaliere F; Botti C; Perri P; Di Filippo S; Di Angelo P; Principi F; Laurenzi L
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):97-101. PubMed ID: 16767914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
